Search
News
Why Palantir Technologies Stock Is Trading Up 4% on Friday
Data analytics firm Palantir Technologies saw its shares climb more than 4% on Friday, following an endorsement from market commentator Jim Cramer, who reaffirmed his optimistic outlook and $200 price target for the company.Cramer pointed out that Palantir, known for its defense-oriented AI software...Tiger News
Sep 12, 2025
Crypto Exchange Gemini Surges 45% in Trading Debut
Crypto exchange Gemini surged 45% in trading debut.Cryptocurrency firm Gemini Space Station raised $425 million in an initial public offering on Thursday, pricing its stock above a marketed range.The company led by the billionaire twins Tyler and Cameron Winklevoss sold around 15.2 million shares fo...Tiger News
Sep 12, 2025
Cafe Chain Black Rock Coffee Bar Jumps 34% in Trading Debut
Cafe Chain Black Rock Coffee Bar jumped 33.6% in trading debut.Black Rock Coffee Bar has raised $294.1 million in its U.S. initial public offering, the cafe chain said on Thursday, setting the stage for a closely-watched consumer listing in the aftermath of the tariff turmoil.The Scottsdale, Arizona...Tiger News
Sep 12, 2025
Trump Officials to Link Child Deaths to Covid Shots, Washington Post Reports
Trump health officials plan to link coronavirus vaccines to the deaths of 25 children as they consider limiting which Americans should get the shots, according to four people familiar with the situation who spoke on the condition of anonymity to describe confidential information, Washington Post rep...Tiger News
Sep 12, 2025
Blockchain Lender Figure Jumps Another 13% After surging 24% on Debut
Blockchain lender Figure jumped another 13% on Friday.Figure Technology shares jumped 24.4% on their Nasdaq debut on Thursday, adding to a run of strong first-day performances by crypto-linked firms as the digital-assets industry edges closer to the mainstream.Figure and some of its backers raised $...Tiger News
Sep 12, 2025
Warner Brothers Discovery and Paramount Skydance Shares Jump on Buyout Reports
Warner Bros. Discovery and Paramount Skydance gained again in morning trading on Friday.Shares in Warner Brothers Discovery and Paramount Skydance have surged on Thursday following reports that Paramount Skydance is preparing an offer to buy the rival studio.The reported bid would be for the entire ...Tiger News
Sep 12, 2025
Super Micro Computer Stock Jumps on Nvidia Blackwell Shipments
Super Micro Computer shares jumped 4.1% on Friday after the company announced it has begun volume shipments of its NVIDIA Blackwell Ultra systems and rack plug-and-play data center-scale solutions to customers worldwide.The San Jose-based company revealed it is now delivering high-volume NVIDIA HGX ...Tiger News
Sep 12, 2025
Apple Postpones Release of New iPhone Air in Mainland China, Bloomberg Reports
Apple Inc. delayed the launch of its new iPhone Air in mainland China, citing regulatory approval issues, Bloomberg reported.Apple shares dropped 0.5% in premarket trading.When pre-orders for the new models began on Friday, the company’s China website would not let customers in the region order the ...Tiger News
Sep 12, 2025
Solana Season Gains Steam as Institutional Demand Surges, Pushing SOL DAT Stocks Higher
TradingKey - Amid strong buying momentum from crypto treasury companies and positive regulatory developments, Galaxy Digital and Bitwise have jointly declared the arrival of “Solana Season.” Solana’s price has surged, with SOL treasury stocks like Upexi and Forward Industries rising double digits in
Pre-Bell｜U.S. Futures Mixed; Microsoft Rises 1%; Micron and Adobe Gain 3%; Super Micro and Warner Bros. Jump 6%
Wall Street futures were mixed on Friday after the three main U.S. indexes hit record highs in the previous session, packing up a week of economic data that did not temper expectations of interest rate cuts from the Federal Reserve.Market SnapshotAt 7:50 a.m. ET, Dow e-minis were down 89 points, or ...Tiger News
Sep 12, 2025
Godfather Meets Barbie? Paramount Skydance in Talks to Acquire Warner Bros., Reshaping Hollywood
TradingKey - The global entertainment industry and financial markets are closely watching a potential blockbuster consolidation: Paramount Skydance’s proposed acquisition of Warner Bros. Discovery (WBD). It sparks visions of cinematic universes colliding — from The Godfather meeting Harry Potter
TradingKey
Sep 12, 2025
Uni-Bio Science Group and Kexing Biopharm Forge Strategic Partnership to Accelerate Global Expansion of Osteoporosis Treatment Bogutai®
Zhangqiu District, Jinan City, Shandong Province – September 2025Uni-Bio Science Group (“the Group”) is pleased to announce the signing of a strategic cooperation agreement with Kexing Biopharm (Stock Code: 688136.SH), a leading biopharmaceutical company with extensive expertise in global commercialization. Under this landmark agreement, Beijing Genetech Pharmaceutical Co., Ltd. (“Beijing Genetech”), a subsidiary of the Group, has granted Kexing Biopharm exclusive rights to commercialize Bogutai® (Teriparatide Injection) in six international markets, including Saudi Arabia, Egypt, Morocco, Colombia, Argentina, and Mexico (“Cooperation Regions”). Bogutai® is expected to complete registration and generate revenue in the Cooperation Regions as early as the end of 2026. The signing ceremony, held in Zhangqiu District, Jinan City, marks a pivotal step in the Group’s international expansion and its commitment to advancing osteoporosis care worldwide.Pioneering Osteoporosis Treatment with Proven ResultsBogutai® is a recombinant human parathyroid hormone analog (PTH1–34), an anabolic treatment for osteoporosis that has been widely recognized for its efficacy and safety. Recommended by numerous domestic and international clinical guidelines, Teriparatide is particularly effective in improving bone microarchitecture and reducing fracture risk in postmenopausal women at high risk of fractures. Since its launch in China in March 2024, Bogutai® has demonstrated rapid market adoption, achieving a remarkable revenue growth of 248.9% year-on-year in the first half of 2025, reaching approximately HK$65.6 million. This impressive performance underscores the strong demand for innovative osteoporosis therapies and highlights the untapped potential of Bogutai® in global markets. Addressing the Global Osteoporosis EpidemicOsteoporosis, often referred to as a “silent killer,” affects over 200 million people globally, with the aging population exacerbating its prevalence. Early-stage osteoporosis is typically asymptomatic, leading to delayed diagnoses and severe complications such as fractures. In China, for example, only 6.5% of individuals receive osteoporosis treatment within six months of a fracture. Similarly, emerging markets across the Middle East and North Africa face low diagnosis and treatment rates despite growing awareness and significant patient populations. Injectable therapies like Teriparatide have been recommended by the Guidelines for Rational Drug Use of Osteoporosis in Primary Care (2021) for patients unable to tolerate oral medications, those with poor adherence, or individuals at high risk of fractures, including elderly patients with multiple vertebral or hip fractures. With its targeted mechanism of action as a bone-forming agent, Bogutai® is uniquely positioned to address this unmet medical need in both established and emerging markets. It is estimated that the osteoporosis market in the Cooperation Regions is nearly USD 1.5 billion, with a patient population exceeding 10 million. A Collaboration Built on Complementary Strengths Commenting on the partnership, Mr. Kingsley Leung, Chairman of Uni-Bio Science Group, said: “Teriparatide Injection is a transformative therapy with immense potential in overseas markets. By partnering with Kexing Biopharm, a company with a robust international commercialization network and proven operational expertise, we are confident in our ability to bring Bogutai® to patients in need across key regions. This collaboration represents a critical step in our mission to improve global bone health.”Mr. Zhao Yanqing, General Manager of Kexing Biopharm, added: “We are excited to join forces with Uni-Bio Science Group to unlock the regional potential of Bogutai®. With our established capabilities in regulatory approvals and market promotion, we aim to accelerate product registration and commercialization, ensuring that this innovative therapy reaches patients quickly and effectively.”Enhancing Global Competitiveness in Osteoporosis CareWith over 20 years of international commercialization experience, Kexing Biopharm has built a strong marketing network spanning the European Union and emerging markets. The addition of Bogutai® to its portfolio complements its existing success with previously introduced denosumab injection, creating a comprehensive suite of osteoporosis treatments that combines “anti-resorptive” and “bone-forming” therapies. This synergy enhances the competitiveness of both companies in addressing the growing global demand for osteoporosis care. For Uni-Bio Science Group, this partnership is a key milestone in its internationalization strategy. Bogutai® is expected to generate revenue in the Cooperation Regions as early as the end of 2026, and with its competitive pricing, it may achieve higher profit margins. Beyond the collaboration with Kexing Biopharm, the Group is actively pursuing FDA approval for Bogutai® in the United States, having already received a waiver for in vivo bioequivalence studies. With this expedited regulatory pathway, FDA approval is anticipated in 2027, further solidifying the Group’s position as a leader in osteoporosis treatment. The Group is also advancing innovative pipeline products, including Uni-PTH (microneedle) for osteoporosis and UB107 (a Class III medical device) for bone repair, reinforcing its commitment to addressing unmet medical needs in bone metabolism and regenerative medicine. Shaping the Future of Osteoporosis TreatmentLooking ahead, Uni-Bio Science Group remains dedicated to expanding its global footprint, deepening strategic partnerships, and accelerating the development of innovative therapies. By bringing Chinese innovation to the world, the Group aims to improve the lives of osteoporosis patients and set new standards in bone health and regenerative medicine. EndAbout Bogutai® (Teriparatide Injection)Bogutai® (Teriparatide Injection) is a biologically expressed recombinant human parathyroid hormone analog (PTH1–34), representing the active 34-amino-acid N-terminal region of the full 84-amino-acid human parathyroid hormone. This advanced therapeutic agent is specifically indicated for postmenopausal women with osteoporosis who are at high risk of fractures.Bogutai® exerts its effects by stimulating osteoblast activity, promoting new bone formation, and increasing bone mineral density (BMD). Unlike antiresorptive therapies that primarily inhibit bone resorption, Bogutai® actively enhances bone remodeling by increasing osteoblast-mediated bone deposition while indirectly regulating osteoclast activity to maintain a balanced bone turnover. This anabolic mechanism makes it a highly effective treatment option for reducing the risk of fractures and improving skeletal integrity in patients with severe osteoporosis.About Uni-Bio Science GroupUni-Bio Science Group Limited (Stock Code: HK 00690) is a biopharmaceutical company dedicated to utilizing new synthetic biology technology to develop next generation regenerative therapies in the orthopedics, ophthalmology, dermatology and medical aesthetics. The Group also has three GMP manufacturing bases in Beijing, Dongguan and Shenzhen. From R&D, production, manufacturing, to sales and distribution of biopharmaceutical and high value chemical drugs and medical-class skincare raw material products, the Group has established a fully integrated business platform serving the entire value chain.About Kexing BiopharmKexing Biopharm (Stock Code: 688136.SH) is a leading multinational biopharmaceutical company. It has established 6 overseas subsidiaries and offices, which have acquired market access and achieved sales in dozens of countries and regions such as the European Union, Brazil, Philippines and Indonesia.12/09/2025 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.comEQS
Sep 12, 2025
Modern Dental Group Signed MoU with Sindan on Developing the First World-class Dental Lab in the UAE by Leveraging Advanced Technology
The MoU signing between Modern Dental Group and Sindan, witnessed by Mr. Nicholas Ho, the Commissioner for Belt and Road.(Hong Kong, 12 September 2025) - Modern Dental Group Limited (“Modern Dental” or “the Group”, stock code: 03600.HK), a leading global dental prosthetic devices provider, was invited to attend the 10th “Belt and Road Summit” co-organized by the Hong Kong Special Administrative Region (HKSAR) Government and the Hong Kong Trade Development Council. The Group has signed a Memorandum of Understanding (MoU) with Sindan, a leading technology manufacturing hub in the United Arab Emirates (UAE) at the Cooperation Agreement Signing Ceremony on 10 September. We will jointly develop the first world-class dental laboratory in the UAE by leveraging advanced manufacturing technologies and dental expertise, accelerating the Group’s swift entry and expansion in the rapidly evolving Middle East and North Africa (MENA) market.Modern Dental Group has been committed to advancing its global dental footprint and has actively facilitated the digital transformation in dentistry to support practitioners worldwide by upgrading treatment plans to provide patients with a more precise and superior comprehensive treatment experience. Sindan, the leading technology manufacturing company in the UAE, specializes in developing innovative technologies for industrial design, production, and deployment of mission-critical components, providing manufacturing solutions across energy, mobility, consumer products, aerospace, and healthcare sectors. This partnership between Modern Dental Group and Sindan has fully demonstrated a mutual high regard for their respective capabilities and expertise in the sector.Modern Dental Group owns a unique global dental distribution network that enables new dental products and solutions to quickly penetrate emerging markets. Through this collaboration, the Group leverages its extensive expertise accumulated over the past decades to establish a strong presence and facilitate rapid access in the dynamic MENA landscape. Our competitive advantage and leading position in the dental supply chain have made us the first global dental hub to cooperate with leading technology pioneer and establish a dental technology collaboration in the UAE, driving new momentum for innovation in the dental field.It is foreseeable that the Group will continue to strengthen its influential position in the industry and attract even greater international capital support in the future, further promoting technological innovation and consolidating the global dental market. Looking ahead, the Group remains committed to its core values of innovation-driven development and win-win cooperation, fully leveraging the established comprehensive dental hub in capturing growing opportunities ahead. We are committed and strategically positioned to partner with global collaborators in delivering innovative and diverse dental solutions, creating a new landscape for international cooperation in the dental field and driving business growth.About Modern Dental Group Modern Dental Group Limited (Stock code: 03600.HK) is a leading global dental prosthetics provider, distributor and consultant with a focus on providing custom-made prostheses to customers in the growing prosthetics industry. Our product portfolio is broadly categorized into three product lines: fixed prosthetic devices, such as crowns and bridges; removable prosthetic devices, such as removable dentures; and other devices, such as orthodontic devices, sports guards, clear aligners, and anti-snoring devices.Modern Dental Group has a global portfolio of respected brands, including Labocast, Permadental and Elysee Dental in Western Europe, YZJ Dental in China, Modern Dental Lab in Hong Kong, Modern Dental USA and MicroDental in the United States, Modern Dental Pacific in Australia and New Zealand, Modern Dental SG in Singapore, Modern Dental TW in Taiwan, Apex Digital Dental in Malaysia and Hexa Ceram in Thailand. We have grown these brands by providing premium and consistent quality products and superior customer service. We have more than 80 service centers in over 28 countries and serve over 35,000 customers.12/09/2025 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.comEQS
Sep 12, 2025
Crypto Stocks Jump With Bitfarms up 10%
Crypto stocks jumped in premarket trading. CleanCore Solutions rose 24%; Asset Entities rose 12%; Bitfarms rose 10%; Upexi and Sharps Technology rose 8%; DeFi Dev rose 5%; BitMine Immersion Technologies rose 4%; SharpLink Gaming rose 3%; Bullish rose 2%; Riot Platforms rose 1%.Tiger News
Sep 12, 2025
Premarket Movers | Ibex Soars 25%; Baidu and Super Micro Jump 5%; Warner Bros and Adobe Gain 4%; RH Sinks 8%
Ibex Limited shares surged 24.6% after the business process outsourcing provider reported fourth quarter earnings and revenue that significantly exceeded analyst expectations, driven by strong performance across its top verticals.Baidu shares jumped 5.1% in premarket trading. China's Alibaba and Bai...Tiger News
Sep 12, 2025
Big RPO, Bigger Risk: Why Oracle’s OpenAI Deal Isn’t the Slam Dunk It Seems
TradingKey - A wave of massive orders from clients like OpenAI has pushed Oracle’s Remaining Performance Obligations (RPO) to $455 billion, fueling a 36% stock surge — yet the rally quickly reversed. Wall Street is raising red flags: Can Oracle actually deliver? And can OpenAI afford to pay?
TradingKey
Sep 12, 2025
Alibaba and Baidu Soar on Adoption of Self-Developed Chips for AI Training
TradingKey - Reports have emerged that Chinese tech giants Alibaba and Baidu have started using self-designed chips to train AI models, partially replacing Nvidia's chips. Following this news, Alibaba's US-listed shares surged by 8% on Thursday, marking the biggest two-week gain, while its Hong Kong
TradingKey
Sep 12, 2025
Microsoft Stock Jumps 2% on OpenAI Restructuring Deal
Microsoft shares climbed nearly 2% in premarket trading on Friday after the company announced a non-binding deal with OpenAI to revise their partnership terms. The agreement, anticipated for months, will allow OpenAI to restructure as a for-profit entity. This marks a major step forward in one of th...Tiger News
Sep 12, 2025
Featured Tools
Top News
Meta Connect 2026 New Product Roundup: Muse Integrated Into AI Glasses, Can It Drive Meta Revenue Growth?
Today’s Market Recap: 10-Year Treasury Yield Hits Highest Level Since 2007, Major U.S. Indexes Fall, SpaceX Drops Over 4%
Qualcomm Extends Long-Term Patent Agreement With Apple, Securing QTL Revenue in Era of In-House iPhone Modems
【US Pre-Market】Nasdaq Leads Losses in Three Major Stock Index Futures, IONQ Surges Over 11%, RGTI Rises Over 5% as Market Focuses on US-China Summit
Oracle Tumbles 7% as Project Jupiter Data Center Force Majeure Notice Sparks Delay Concerns
